Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
|Videos|February 8, 2021
A 68-Year-Old Woman with Small-Cell Lung Cancer
Author(s)Kartik Konduri, MD
Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.
Advertisement
Case: A 68-Year-Old Woman with Extensive-Stage Small-Cell Lung Cancer
Initial Presentation
- A 68-year-old woman presented with fatigue and a cough
- PMH/PSH: hysterectomy at age 55
- SH: 55-pack year smoking history
- PE: decreased breath sounds in the left lung, cervical lymph node enlargement
Clinical Workup
- Labs: WNL
- Lymph node biopsy showed small cell carcinoma
- Chest/abdomen/pelvic CT showed a 7.4 cm mass above the diaphragm, a small contralateral lung nodule and evidence of invasion into the left side of the pericardium
- PET scan showed activity in both lungs, above the diaphragm with small hypermetabolic activity in the surrounding area
- Contrast‐enhanced MRI of the head was negative for brain metastases
- Stage IV extensive-stage small-cell lung cancer; ECOG PS 0
Treatment
- Initiated carboplatin + etoposide + atezolizumab for 4 cycles; followed with atezolizumab as maintenance therapy
- Repeat CT scan showed a suspicious hepatic mass
- Initiated lurbinectedin 3.2 mg/m2 IV q21 Days
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
3
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
4
AI in Precision Oncology: A Paradigm Shift
5